For the quarter ending 2025-09-30, BDSX had -$4,124K decrease in cash & cash equivalents over the period. -$8,927K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Revenues | 59,744 | - |
| Direct costs and expenses (less employee related expenses and depreciation and amortization) | 8,634 | - |
| Employee related expenses (less share-based compensation expenses) | 48,703 | - |
| Contracted services expenses | 5,691 | - |
| Sales and marketing education and event expenses | 5,601 | - |
| Occupancy and equipment service expenses | 3,079 | - |
| Clinical trials and associated costs | 1,287 | - |
| Depreciation and amortization expense | 1,407 | - |
| Share-based compensation expenses | 3,064 | - |
| Interest expense | 5,657 | - |
| Change in fair value of warrant liability, net | 0 | - |
| Other segment items | 4,750 | - |
| Net loss | -8,716 | -22,569 |
| Depreciation and amortization | 1,407 | 2,876 |
| Accretion of lease right-of-use assets | -29 | -59 |
| Share-based compensation expense | 1,053 | 2,011 |
| Change in fair value of warrant liability, net | 0 | 280 |
| Provision for credit losses | 0 | 109 |
| Accrued interest, amortization of debt issuance costs and other | 332 | 639 |
| Inventory excess and obsolescence | 10 | 11 |
| Impairment loss on intangible assets | 7 | 99 |
| Accounts receivable | 5,224 | -1,085 |
| Other current assets | -16 | -318 |
| Other long-term assets | 125 | 5 |
| Accounts payable and other accrued liabilities | 486 | 399 |
| Deferred revenue | 2,128 | -114 |
| Current and long-term operating lease liabilities | -224 | -250 |
| Net cash, cash equivalents, and restricted cash used in operating activities | -8,879 | -15,170 |
| Purchase of property and equipment | 48 | 125 |
| Patent costs and intangible asset acquisition, net | 19 | 107 |
| Net cash, cash equivalents, and restricted cash used in investing activities | -67 | -232 |
| Proceeds from the issuance of common stock | 5,000 | - |
| Proceeds from issuance of common stock under employee stock purchase plan | 184 | 313 |
| Proceeds from term loan and notes payable | 0 | 10,000 |
| Repayment of term loan and notes payable | 4 | 12 |
| Payment of debt issuance costs | 3 | 27 |
| Equity financing costs | 188 | - |
| Other | -167 | -388 |
| Net cash, cash equivalents, and restricted cash provided by financing activities | 4,822 | 9,886 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -4,124 | -5,516 |
| Cash and cash equivalents at beginning of period | 26,332 | - |
| Cash and cash equivalents at end of period | 16,692 | - |
BIODESIX INC (BDSX)
BIODESIX INC (BDSX)